Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · Real-Time Price · USD
1.530
-0.010 (-0.65%)
Nov 3, 2025, 4:00 PM EST - Market closed
Calidi Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
28
Market Cap
6.16M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 45.00K | -404.00K | -89.98% |
| Dec 31, 2021 | 449.00K | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
CLDI News
- 2 months ago - Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option - GlobeNewsWire
- 2 months ago - Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering - GlobeNewsWire
- 3 months ago - Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights - GlobeNewsWire
- 3 months ago - Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025 - GlobeNewsWire
- 3 months ago - Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on July 24 - GlobeNewsWire
- 4 months ago - Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment - GlobeNewsWire
- 4 months ago - Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds - GlobeNewsWire
- 4 months ago - Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment - GlobeNewsWire